274
KNDP 당뇨병 임상 진료지침 Clinical Practice Guidelines

22. we monitoring for hyperkalemia? Ann Pharmacother 2007;41:193-200.
23. Raebel MA, Ross C, Xu S, et al. Diabetes and drug-associated hyperkalemia: Effect of potassium monitoring. J Gen Intern Med 2010;25:326-33.
24. Feuvray D, Darmellah A. Diabetes-related metabolic perturbations in cardiac myocyte. Diabetes Metab 2008;34(suppl 1):3-9.
25. Wenmeng W, Qizhu T. Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy. Med Hypotheses 2011;76:181-3.
26. Belardinelli R, Cianci G, Gigli M, et al. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. J Cardiovasc Pharmacol 2008;51:611-5.
27. Bell DS, Lukas MA, Holdbrook FK, et al. The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Curr Med Res Opin 2006;22:287-96.
28. Salpeter S, Greyber E, Pasternak P, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;(4): CD 002967.
29. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Arch Intern Med 2003;163:2594-602.